Investigating how specific cell signaling affects nerve damage from chemotherapy
The role of cell-specific TLR-4 signaling in oxaliplatin-induced peripheral neuropathy
This study is looking at how the chemotherapy drug oxaliplatin causes nerve damage in colorectal cancer patients and is exploring whether some already-approved medications can help prevent or treat this nerve pain to improve the lives of cancer survivors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10442405 on NIH RePORTER |
What this research studies
This research focuses on understanding how oxaliplatin, a chemotherapy drug, causes nerve damage known as chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer patients. The study aims to explore the mechanisms behind this nerve damage and evaluate whether existing FDA-approved drugs can be repurposed to prevent or treat CIPN. By examining specific pathways and receptors involved in this process, the research seeks to identify potential therapeutic targets that could improve the quality of life for cancer survivors suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are colorectal cancer patients who have experienced or are at risk of developing chemotherapy-induced peripheral neuropathy.
Not a fit: Patients who have not undergone chemotherapy or those with other unrelated neurological conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that alleviate or prevent nerve damage caused by chemotherapy, significantly improving the quality of life for cancer survivors.
How similar studies have performed: Previous research has shown promise in repurposing FDA-approved drugs for similar conditions, indicating potential success for this approach.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: White, Fletcher a — Indiana University Indianapolis
- Study coordinator: White, Fletcher a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.